Tenaya Therapeutics (TNYA) Shares Outstanding (Diluted Average) (2021 - 2026)
Tenaya Therapeutics' quarterly Shares Outstanding (Diluted Average) came in at $216.9 million in Q1 2026, up 97.4% year-on-year from $109.9 million in Q1 2025, and up 41.78% quarter-over-quarter from $153.0 million in Q4 2025.
Tenaya Therapeutics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $216.9 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 97.4% year-over-year to $216.9 million; the trailing twelve-month figure through Mar 2026 stood at $216.9 million (up 97.4% YoY), and the FY2025 full-year result was $153.0 million, up 80.34% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $216.9 million, up from $153.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $216.9 million in Q1 2026, with the low at $41.3 million in Q1 2022.
- Average Shares Outstanding (Diluted Average) over 5 years is $92.7 million, with a median of $81.0 million recorded in 2024.
- Year-over-year, Shares Outstanding (Diluted Average) jumped 321.18% in 2022 and gained 10.79% in 2024.
- Tracing TNYA's Shares Outstanding (Diluted Average) over 5 years: stood at $44.8 million in 2022, then jumped by 64.61% to $73.8 million in 2023, then climbed by 14.96% to $84.8 million in 2024, then surged by 80.34% to $153.0 million in 2025, then jumped by 41.78% to $216.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $216.9 million (Q1 2026), $153.0 million (Q4 2025), and $163.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | 216.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 216.88 Mn |
| Dec 31, 2025 | 152.97 Mn |
| Sep 30, 2025 | 163.35 Mn |
| Jun 30, 2025 | 136.48 Mn |
| Mar 31, 2025 | 109.87 Mn |
| Dec 31, 2024 | 84.82 Mn |
| Sep 30, 2024 | 84.29 Mn |
| Jun 30, 2024 | 83.34 Mn |
| Mar 31, 2024 | 80.98 Mn |
| Dec 31, 2023 | 73.79 Mn |
| Sep 30, 2023 | 73.58 Mn |
| Jun 30, 2023 | 73.25 Mn |
| Mar 31, 2023 | 73.10 Mn |
| Dec 31, 2022 | 44.82 Mn |
| Sep 30, 2022 | 41.31 Mn |
| Jun 30, 2022 | 41.29 Mn |
| Mar 31, 2022 | 41.27 Mn |
| Dec 31, 2021 | 17.73 Mn |
| Sep 30, 2021 | 9.81 Mn |